Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVER-TIME II in ACS and CAE
NCT07511257Phase 4Recruiting
- Sponsor
- Instituto Nacional de Cardiología Ignacio Chávez
- Start
- Feb 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in acute coronary syndrome (ACS), Coronary artery ectasia (CAE), sponsored by Instituto Nacional de Cardiología Ignacio Chávez. Started Feb 2026; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)Coronary artery ectasia (CAE)
Beyond the preview
Go deeper on NCT07511257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511257.